-DOCSTART-	O

Title	O
:	O
Physiological	B-I
pacing	I-I
improves	O
symptoms	O
and	O
increases	O
exercise	O
capacity	O
in	O
the	B-P
elderly	I-P
patient	I-P
.	O

-DOCSTART-	O

Title	O
:	O
Interferon	B-I
treatment	I-I
for	O
hairy	O
cell	O
leukemia	O
.	O

An	O
update	O
on	O
a	B-P
cohort	I-P
of	I-P
69	I-P
patients	I-P
treated	I-P
from	I-P
1983	I-P
to	I-P
1986	I-P
.	O

METHODS	O
:	O
Follow	O
-	O
up	O
through	O
April	O
,	O
1993	O
shows	O
that	O
only	O
14	O
patients	O
have	O
expired	O
.	O

-DOCSTART-	O

Title	O
:	O
Naltrexone	B-I
in	O
young	B-P
autistic	I-P
children	I-P
:	O
a	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
crossover	O
study	O
.	O

METHODS	O
:	O
Thirteen	B-P
children	I-P
with	I-P
autistic	I-P
disorder	I-P
,	I-P
aged	I-P
3	I-P
.	I-P
4	I-P
to	I-P
8	I-P
.	I-P
3	I-P
years	I-P
(	I-P
mean	I-P
5	I-P
.	I-P
4	I-P
)	I-P
,	I-P
were	I-P
studied	I-P
in	I-P
home	I-P
,	I-P
school	I-P
,	I-P
and	I-P
outpatient	I-P
laboratory	I-P
.	O

Naltrexone	B-I
,	O
1	O
.	O
0	O
mg	O
/	O
kg	O
,	O
was	O
given	O
daily	O
in	O
a	O
randomized	O
,	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
crossover	O
design	O
.	O

Dependent	O
measures	O
included	O
parent	B-O
and	I-O
teacher	I-O
Clinical	I-O
Global	I-O
Impressions	I-O
(	I-O
CGI	I-O
)	I-O
,	O
Conners	B-O
Rating	I-O
Scales	I-O
,	O
and	O
Naltrexone	B-O
Side	I-O
-	I-O
Effects	I-O
(	I-O
SE	I-O
)	I-O
Rating	I-O
Scale	I-O
;	O
laboratory	B-O
CGI	I-O
,	O
movement	B-O
actometer	I-O
readings	I-O
,	O
and	O
a	B-O
10	I-O
-	I-O
second	I-O
interval	I-O
recording	I-O
system	I-O
analysis	O
of	O
on	O
-	O
task	O
,	O
communication	B-O
initiations	I-O
,	O
disruptive	B-O
behavior	I-O
,	O
and	O
self	B-O
-	I-O
stimulation	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Evaluation	O
of	O
an	O
intervention	O
to	O
change	O
benzodiazepine	O
-	O
prescribing	O
behavior	O
in	O
a	O
prepaid	O
group	O
practice	O
setting	O
.	O

METHODS	O
:	O
Our	O
setting	O
was	O
a	O
270	O
,	O
000	O
member	O
group	O
-	O
model	O
PPGP	O
in	O
Colorado	O
,	O
from	O
1990	O
to	O
1991	O
.	O

Participants	B-P
included	I-P
91	I-P
physicians	I-P
,	I-P
62	I-P
men	I-P
and	I-P
29	I-P
women	I-P
;	I-P
median	I-P
age	I-P
was	I-P
38	I-P
.	I-P
7	I-P
years	I-P
.	O

Group	O
1	O
received	O
a	B-I
one	I-I
-	I-I
on	I-I
-	I-I
one	I-I
educational	I-I
presentation	I-I
by	I-I
a	I-I
clinical	I-I
pharmacist	I-I
,	O
written	B-I
educational	I-I
materials	I-I
,	O
a	B-I
brief	I-I
follow	I-I
-	I-I
up	I-I
visit	I-I
,	O
and	O
feedback	B-I
with	I-I
recommendations	I-I
.	O

Group	O
2	O
received	O
only	B-I
a	I-I
face	I-I
-	I-I
to	I-I
-	I-I
face	I-I
presentation	I-I
,	O
given	B-I
to	I-I
departmental	I-I
groups	I-I
,	O
as	O
well	O
as	O
the	B-I
same	I-I
written	I-I
educational	I-I
materials	I-I
used	I-I
in	I-I
group	I-I
1	I-I
.	O

Controls	O
received	O
no	B-C
intervention	I-C
.	O

Our	O
primary	O
outcome	O
measure	O
was	O
the	B-O
benzodiazepine	I-O
"	I-O
on	I-O
/	I-O
off	I-O
"	I-O
status	I-O
of	I-O
the	I-O
elderly	I-O
PPGP	I-O
members	I-O
.	O

The	O
secondary	O
outcome	O
measure	O
was	O
the	O
median	O
change	O
(	O
preintervention	O
minus	O
postintervention	O
)	O
in	O
a	B-O
standardized	I-O
amount	I-O
of	I-O
benzodiazepines	I-O
prescribed	I-O
per	I-O
physician	I-O
.	O

-DOCSTART-	O

Title	O
:	O
[	O
Report	O
of	O
a	O
controlled	O
clinical	O
trial	O
of	O
a	O
new	O
synthetic	O
drug	O
,	O
parsalmide	B-I
,	O
in	O
rheumatic	O
arthropathies	O
(	O
inflammatory	O
and	O
degenerative	O
)	O
]	O
.	O

METHODS	O
:	O
The	O
study	O
was	O
carried	O
out	O
in	O
30	B-P
subjects	I-P
using	O
the	O
controlled	O
experiment	O
technique	O
according	O
to	O
the	O
"	O
between	O
patient	O
"	O
pattern	O
,	O
attributing	O
parsalmide	B-I
and	O
indomethacin	B-I
at	O
random	O
to	O
two	O
groups	O
.	O

-DOCSTART-	O

Title	O
:	O
Effects	O
of	O
a	B-I
fish	I-I
-	I-I
oil	I-I
and	O
vegetable	B-I
-	I-I
oil	I-I
formula	I-I
on	O
aggregation	O
and	O
ethanolamine	O
-	O
containing	O
lysophospholipid	O
generation	O
in	O
activated	O
human	O
platelets	O
and	O
on	O
leukotriene	O
production	O
in	O
stimulated	O
neutrophils	O
.	O

METHODS	O
:	O
The	O
effects	O
of	O
consuming	O
a	B-I
liquid	I-I
formula	I-I
containing	I-I
either	I-I
fish	I-I
oil	I-I
enriched	I-I
in	I-I
omega	I-I
-	I-I
3	I-I
fatty	I-I
acids	I-I
or	O
vegetable	B-I
oil	I-I
enriched	I-I
in	I-I
oleic	I-I
acid	I-I
was	O
evaluated	O
in	O
20	B-P
male	I-P
subjects	I-P
randomly	O
allocated	O
into	O
two	O
groups	O
over	O
a	O
42	O
-	O
d	O
period	O
.	O

-DOCSTART-	O

Title	O
:	O
Brief	O
report	O
:	O
a	O
controlled	O
evaluation	O
of	O
facilitated	O
communication	O
using	O
open	B-I
-	I-I
ended	I-I
and	O
fill	B-I
-	I-I
in	I-I
questions	I-I
.	O

-DOCSTART-	O

Title	O
:	O
Peripheral	B-I
intravenous	I-I
line	I-I
survival	O
and	O
phlebitis	O
prevention	O
in	O
patients	B-P
receiving	I-P
intravenous	I-P
antibiotics	I-P
:	O
heparin	B-I
/	O
hydrocortisone	B-I
versus	O
in	B-I
-	I-I
line	I-I
filters	I-I
.	O

METHODS	O
:	O
Patients	B-P
with	I-P
cystic	I-P
fibrosis	I-P
receiving	I-P
intermittent	I-P
i	I-P
.	I-P
v	I-P
.	I-P
antibiotics	I-P
were	O
randomly	O
allocated	O
to	O
receive	O
their	O
drugs	O
either	O
through	O
an	B-I
in	I-I
-	I-I
line	I-I
filter	I-I
using	O
a	B-I
drug	I-I
-	I-I
free	I-I
infusate	I-I
or	O
with	B-I
no	I-I
filter	I-I
and	O
an	B-I
infusate	I-I
containing	I-I
heparin	I-I
500	O
units	O
and	O
hydrocortisone	B-I
10	O
mg	O
/	O
L	O
.	O

Infusion	B-O
sites	I-O
were	O
assessed	O
daily	O
.	O

-DOCSTART-	O

Title	O
:	O
Videofluoroscopic	O
evidence	O
of	O
aspiration	O
predicts	O
pneumonia	O
and	O
death	O
but	O
not	O
dehydration	O
following	O
stroke	O
.	O

METHODS	O
:	O
The	B-I
videofluoroscopic	I-I
modified	I-I
barium	I-I
swallow	I-I
technique	I-I
included	O
5	B-I
ml	I-I
-	I-I
thin	I-I
and	O
thick	B-I
liquid	I-I
barium	I-I
,	O
5	B-I
ml	I-I
barium	I-I
pudding	I-I
,	O
and	O
1	B-I
/	I-I
4	I-I
cookie	I-I
coated	I-I
with	I-I
barium	I-I
,	O
plus	O
additional	B-I
20	I-I
and	O
30	B-I
ml	I-I
of	I-I
thin	I-I
liquid	I-I
barium	I-I
.	O

Patients	O
were	O
assessed	O
a	O
mean	O
of	O
2	O
+	O
/	O
-	O
1	O
SD	O
months	O
poststroke	O
and	O
were	O
followed	O
for	O
a	O
mean	O
of	O
16	O
+	O
/	O
-	O
8	O
SD	O
months	O
poststroke	O
.	O

-DOCSTART-	O

Title	O
:	O
Cyclosporin	B-I
versus	O
cyclophosphamide	B-I
for	O
patients	B-P
with	I-P
steroid	I-P
-	I-P
dependent	I-P
and	I-P
frequently	I-P
relapsing	I-P
idiopathic	I-P
nephrotic	I-P
syndrome	I-P
:	O
a	O
multicentre	O
randomized	O
controlled	O
trial	O
.	O

METHODS	O
:	O
Open	O
,	O
prospective	O
,	O
randomized	O
,	O
multicentre	O
,	O
controlled	O
study	O
for	O
parallel	O
groups	O
,	O
stratified	O
for	O
adults	O
and	O
children	O
.	O

The	O
setting	O
was	O
in	O
nephrological	O
departments	O
in	O
Italy	O
.	O

Seventy	B-P
-	I-P
three	I-P
patients	I-P
with	I-P
steroid	I-P
-	I-P
sensitive	I-P
idiopathic	I-P
NS	I-P
admitted	I-P
to	I-P
the	I-P
study	I-P
were	O
randomly	O
assigned	O
to	O
cyclophosphamide	B-I
(	O
2	O
.	O
5	O
mg	O
/	O
kg	O
/	O
day	O
)	O
for	O
8	O
weeks	O
or	O
CsA	B-I
(	O
5	O
mg	O
/	O
kg	O
/	O
day	O
in	O
adults	O
,	O
6	O
mg	O
/	O
kg	O
/	O
day	O
in	O
children	O
)	O
for	O
9	O
months	O
,	O
tapered	O
off	O
by	O
25	O
%	O
every	O
month	O
until	O
complete	O
discontinuation	O
at	O
month	O
12	O
.	O

Seven	O
patients	O
lost	O
to	O
follow	O
up	O
were	O
not	O
considered	O
in	O
the	O
analysis	O
.	O

The	O
remaining	O
66	O
patients	O
were	O
followed	O
up	O
for	O
3	O
-	O
24	O
months	O
after	O
randomization	O
.	O

Relapse	B-O
-	I-O
free	I-O
survival	I-O
;	O
number	B-O
of	I-O
N	I-O
.	I-O
S	I-O
.	I-O
relapses	I-O
/	I-O
patient	I-O
/	I-O
year	I-O
;	O
cumulative	B-O
dose	I-O
of	I-O
prednisone	I-O
/	I-O
patient	I-O
;	O
laboratory	B-O
investigations	I-O
(	O
kidney	B-O
and	O
liver	B-O
functions	I-O
,	O
haematological	B-O
parameters	I-O
)	O
;	O
incidence	B-O
of	I-O
adverse	I-O
events	I-O
.	O

-DOCSTART-	O

Title	O
:	O
High	O
purity	O
factor	O
VIII	O
and	O
immune	O
state	O
in	O
HIV	O
.	O

-DOCSTART-	O

Title	O
:	O
A	O
double	O
-	O
blind	O
comparison	O
of	O
oral	B-I
ketoprofen	I-I
'	O
controlled	O
release	O
'	O
and	O
indomethacin	B-I
suppository	I-I
in	O
the	O
treatment	O
of	O
rheumatoid	O
arthritis	O
with	O
special	O
regard	O
to	O
morning	O
stiffness	O
and	O
pain	O
on	O
awakening	O
.	O

METHODS	O
:	O
Patients	O
were	O
allocated	O
at	O
random	O
to	O
receive	O
a	O
daily	O
bedtime	O
dose	O
of	O
either	O
1	B-I
ketoprofen	I-I
tablet	I-I
or	O
1	B-I
indomethacin	I-I
suppository	I-I
plus	O
the	B-I
dummy	I-I
of	I-I
the	I-I
other	I-I
formulation	I-I
for	O
a	O
period	O
of	O
3	O
weeks	O
.	O

They	O
were	O
then	O
crossed	O
over	O
to	O
the	O
alternative	O
treatment	O
for	O
a	O
further	O
3	O
weeks	O
.	O

Daily	B-O
diary	I-O
records	I-O
were	O
kept	O
by	O
patients	O
of	O
the	B-O
number	I-O
of	I-O
night	I-O
-	I-O
time	I-O
awakenings	I-O
due	I-O
to	I-O
pain	I-O
,	O
pain	B-O
severity	I-O
at	I-O
awakening	I-O
in	I-O
the	I-O
morning	I-O
and	O
the	B-O
duration	I-O
of	I-O
early	I-O
morning	I-O
stiffness	I-O
.	O

Treatment	B-O
efficacy	I-O
was	O
also	O
assessed	O
at	O
the	O
end	O
of	O
each	O
trial	O
period	O
by	O
means	O
of	O
an	B-O
articular	I-O
index	I-O
and	O
by	O
physician	B-O
'	I-O
s	I-O
and	O
patient	B-O
'	I-O
s	I-O
overall	I-O
evaluation	I-O
of	I-O
response	I-O
.	O

Adverse	B-O
effects	I-O
spontaneously	O
mentioned	O
by	O
the	O
patients	O
or	O
elicited	O
by	O
direct	O
questioning	O
using	O
a	B-O
symptom	I-O
check	I-O
-	I-O
list	I-O
were	O
recorded	O
.	O

-DOCSTART-	O

Title	O
:	O
Comparison	O
of	O
tidal	O
volumes	O
obtained	O
by	O
one	B-I
-	I-I
handed	I-I
and	O
two	B-I
-	I-I
handed	I-I
ventilation	I-I
techniques	I-I
.	O

METHODS	O
:	O
Subjects	B-P
(	I-P
108	I-P
healthcare	I-P
providers	I-P
from	I-P
a	I-P
500	I-P
-	I-P
bed	I-P
teaching	I-P
hospital	I-P
)	I-P
were	O
assigned	O
randomly	O
to	O
one	O
of	O
two	O
procedures	O
:	O
one	O
-	O
followed	O
by	O
two	B-I
-	I-I
handed	I-I
compression	I-I
or	O
two	O
-	O
followed	O
by	O
one	B-I
-	I-I
handed	I-I
compression	I-I
.	O

A	B-O
1	I-O
-	I-O
liter	I-O
resuscitation	I-O
bag	I-O
,	O
lung	B-O
performance	I-O
analyzer	I-O
and	O
Wright	B-O
spirometer	I-O
were	O
used	O
to	O
measure	O
tidal	B-O
volume	I-O
.	O

Data	O
collection	O
occurred	O
in	O
a	O
simulated	O
situation	O
.	O

-DOCSTART-	O

Title	O
:	O
Omeprazole	B-I
ameliorates	O
aspirin	O
-	O
induced	O
gastroduodenal	O
injury	O
.	O

METHODS	O
:	O
Twenty	B-P
healthy	I-P
volunteers	I-P
were	O
randomized	O
to	O
a	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
,	O
crossover	O
study	O
to	O
determine	O
if	O
omeprazole	B-I
,	O
40	O
mg	O
/	O
day	O
prevents	O
gastroduodenal	B-O
injury	I-O
due	O
to	O
two	O
weeks	O
of	O
aspirin	O
administration	O
(	O
650	O
mg	O
four	O
times	O
a	O
day	O
)	O
.	O

The	B-O
severity	I-O
of	I-O
mucosal	I-O
injury	I-O
was	O
quantitated	O
by	O
endoscopy	B-O
and	O
stratified	O
by	O
a	B-O
scale	I-O
from	I-O
0	I-O
(	I-O
normal	I-O
)	I-O
to	I-O
4	I-O
(	I-O
ulcer	I-O
)	I-O
.	O

-DOCSTART-	O

Title	O
:	O
A	O
multicenter	O
study	O
on	O
the	O
use	O
of	O
pulsed	B-I
low	I-I
-	I-I
intensity	I-I
direct	I-I
current	I-I
for	O
healing	O
chronic	O
stage	O
II	O
and	O
stage	O
III	O
decubitus	O
ulcers	O
.	O

METHODS	O
:	O
Pulsed	B-I
low	I-I
-	I-I
intensity	I-I
direct	I-I
current	I-I
(	O
300	O
to	O
600	O
microA	O
)	O
has	O
been	O
used	O
in	O
a	O
double	O
-	O
blind	O
placebo	O
multicenter	O
study	O
in	O
the	O
treatment	O
of	O
stage	O
II	O
and	O
stage	O
III	O
chronic	O
decubitus	O
ulcers	O
.	O

-DOCSTART-	O

Title	O
:	O
Cimetidine	B-I
is	O
not	O
more	O
effective	O
than	O
placebo	B-C
in	O
acute	O
infectious	O
mononucleosis	O
.	O

-DOCSTART-	O

Title	O
:	O
Effect	O
of	O
reduced	B-I
alcohol	I-I
consumption	I-I
on	O
blood	O
pressure	O
in	O
untreated	B-P
hypertensive	I-P
men	I-P
.	O

METHODS	O
:	O
The	O
purpose	O
of	O
the	O
trial	O
was	O
to	O
test	O
the	O
effects	O
of	O
alcohol	B-I
reduction	I-I
on	O
blood	B-O
pressure	I-O
.	O

After	O
a	O
2	O
-	O
week	O
familiarization	O
period	O
,	O
the	O
participants	O
were	O
assigned	O
to	O
either	O
a	B-I
reduced	I-I
alcohol	I-I
drinking	I-I
group	O
or	O
a	B-C
usual	I-C
drinking	I-C
group	O
for	O
3	O
weeks	O
(	O
experimental	O
period	O
1	O
)	O
.	O

The	O
situation	O
was	O
then	O
reversed	O
for	O
the	O
next	O
3	O
weeks	O
(	O
experimental	O
period	O
2	O
)	O
.	O

The	O
participants	O
were	O
requested	O
to	O
limit	O
their	O
daily	O
alcohol	O
consumption	O
to	O
zero	O
or	O
reduce	O
it	O
as	O
much	O
as	O
possible	O
for	O
the	O
reduced	O
alcohol	O
consumption	O
period	O
.	O

-DOCSTART-	O

Title	O
:	O
[	O
Prevention	O
of	O
pneumonia	O
by	O
endotracheal	B-I
micronebulization	I-I
of	I-I
tobramycin	I-I
]	O
.	O

-DOCSTART-	O

Title	O
:	O
A	O
clinical	O
evaluation	O
of	O
a	B-I
blood	I-I
conservation	I-I
device	I-I
in	O
medical	B-P
intensive	I-P
care	I-P
unit	I-P
patients	I-P
.	O

METHODS	O
:	O
Prospective	O
,	O
randomized	O
,	O
controlled	O
trial	O
.	O

A	O
clinical	O
trial	O
using	O
prospective	O
,	O
random	O
allocation	O
of	O
consecutive	O
eligible	O
patients	O
.	O

The	O
medical	O
intensive	O
care	O
unit	O
(	O
ICU	O
)	O
of	O
a	O
university	O
hospital	O
located	O
in	O
a	O
large	O
metropolitan	O
area	O
.	O

A	B-P
total	I-P
of	I-P
100	I-P
patients	I-P
who	I-P
were	I-P
admitted	I-P
to	I-P
the	I-P
medical	I-P
ICU	I-P
,	I-P
required	I-P
arterial	I-P
line	I-P
monitoring	I-P
for	I-P
clinical	I-P
purposes	I-P
,	I-P
and	I-P
were	I-P
managed	I-P
by	I-P
the	I-P
ICU	I-P
medical	I-P
service	I-P
.	O

Exclusion	O
criteria	O
included	O
active	O
bleeding	O
or	O
chronic	O
renal	O
failure	O
at	O
the	O
time	O
of	O
ICU	O
admission	O
.	O

Patients	O
in	O
the	O
experimental	O
group	O
had	O
a	B-I
blood	I-I
conservation	I-I
device	I-I
incorporated	O
into	O
the	O
arterial	O
pressure	O
monitoring	O
system	O
,	O
while	O
patients	O
in	O
the	O
control	O
group	O
received	O
a	B-C
conventional	I-C
arterial	I-C
pressure	I-C
monitoring	I-C
system	I-C
.	O

-DOCSTART-	O

Title	O
:	O
Recurrence	O
of	O
condylomata	O
acuminata	O
following	O
cryotherapy	O
is	O
not	O
prevented	O
by	O
systemically	B-I
administered	I-I
interferon	I-I
.	O

METHODS	O
:	O
Randomised	O
,	O
placebo	O
-	O
controlled	O
,	O
double	O
-	O
blind	O
study	O
.	O

Statistical	O
analysis	O
was	O
by	O
2	O
-	O
tailed	O
Fisher	O
'	O
s	O
Exact	O
Test	O
.	O

97	B-P
patients	I-P
with	I-P
recurrent	I-P
condylomata	I-P
acuminata	I-P
.	O

49	O
patients	O
were	O
treated	O
with	O
cryotherapy	O
plus	O
subcutaneously	O
administered	O
interferon	B-I
alpha	I-I
-	I-I
2a	I-I
,	O
and	O
48	O
received	O
cryotherapy	B-I
plus	O
placebo	B-C
.	O

Of	O
these	O
,	O
36	O
and	O
37	O
patients	O
,	O
respectively	O
,	O
completed	O
the	O
study	O
and	O
were	O
evaluable	O
.	O

Clinical	B-O
eradication	I-O
of	I-O
condylomata	I-O
for	O
six	O
months	O
following	O
adjuvant	O
chemotherapy	O
.	O

-DOCSTART-	O

Title	O
:	O
0	B-I
.	I-I
1	I-I
%	I-I
bupivacaine	I-I
does	O
not	O
reduce	O
the	O
requirement	O
for	O
epidural	O
fentanyl	O
infusion	O
after	O
major	O
abdominal	O
surgery	O
.	O

METHODS	O
:	O
Forty	B-P
patients	I-P
were	O
randomly	O
assigned	O
to	O
receive	O
either	O
fentanyl	B-I
(	O
10	O
micrograms	O
/	O
mL	O
)	O
or	O
a	B-I
fentanyl	I-I
/	O
bupivacaine	B-I
(	O
0	O
.	O
1	O
%	O
)	O
mixture	O
epidurally	O
corresponding	O
to	O
the	O
dermatome	O
of	O
the	O
surgical	O
incision	O
in	O
a	O
double	O
-	O
blind	O
fashion	O
for	O
the	O
first	O
18	O
hours	O
after	O
major	O
abdominal	O
surgery	O
.	O

The	O
infusion	O
was	O
titrated	O
for	O
each	O
patient	O
to	O
the	O
rate	O
required	O
for	O
pain	O
relief	O
during	O
forced	O
inspiration	O
(	O
pain	O
score	O
<	O
or	O
=	O
2	O
,	O
maximum	O
10	O
)	O
.	O

Pain	B-O
scores	I-O
,	O
the	B-O
fentanyl	I-O
doses	I-O
required	I-O
,	O
plasma	B-O
concentrations	I-O
of	I-O
fentanyl	I-O
at	O
18	O
hours	O
,	O
and	O
the	B-O
incidence	I-O
and	O
severity	B-O
of	I-O
adverse	I-O
effects	I-O
were	O
recorded	O
.	O

-DOCSTART-	O

Title	O
:	O
Measurement	O
of	O
health	O
-	O
related	O
quality	O
of	O
life	O
in	O
multiple	O
myeloma	O
.	O

Nordic	O
Myeloma	O
Study	O
Group	O
.	O

METHODS	O
:	O
We	O
used	O
the	B-I
questionnaire	I-I
(	I-I
QLQ	I-I
-	I-I
C30	I-I
)	I-I
developed	O
by	O
the	O
European	O
Organization	O
of	O
Research	O
and	O
Treatment	O
of	O
Cancer	O
(	O
EORTC	O
)	O
Study	O
Group	O
on	O
Quality	O
of	O
Life	O
.	O

The	B-I
QLQ	I-I
-	I-I
C30	I-I
incorporates	O
five	B-O
functional	I-O
scales	I-O
,	O
three	B-O
symptom	I-O
scales	I-O
,	O
a	B-O
global	I-O
health	I-O
and	O
quality	B-O
-	I-O
of	I-O
life	I-O
scale	I-O
and	O
some	B-O
single	I-O
symptom	I-O
measures	I-O
.	O

The	B-I
questionnaire	I-I
was	O
completed	O
prior	O
to	O
treatment	O
and	O
after	O
1	O
,	O
6	O
,	O
12	O
,	O
24	O
,	O
36	O
and	O
48	O
months	O
.	O

-DOCSTART-	O

Title	O
:	O
Processing	O
familiar	B-I
and	O
unfamiliar	B-I
auditory	I-I
stimuli	I-I
during	O
general	O
anesthesia	O
.	O

METHODS	O
:	O
Stimuli	B-I
were	O
presented	O
via	O
headphones	O
and	O
consisted	O
of	O
common	B-C
facts	I-C
(	O
Group	O
A	O
,	O
29	O
patients	O
)	O
,	O
or	O
familiar	B-I
or	O
unfamiliar	B-I
full	I-I
names	I-I
of	I-I
fictitious	I-I
people	I-I
(	O
GRoup	O
B	O
,	O
29	O
patients	O
)	O
.	O

Group	O
A	O
was	O
expected	O
to	O
give	O
more	O
correct	B-O
answers	I-O
to	I-O
questions	I-O
about	I-O
the	I-O
common	I-O
facts	I-O
than	O
Group	O
B	O
,	O
when	O
tested	O
postoperatively	O
,	O
and	O
Group	O
B	O
to	O
attribute	O
more	O
fame	O
to	O
presented	O
names	O
than	O
Group	O
A	O
(	O
famous	B-O
names	I-O
test	I-O
)	O
.	O

Because	O
the	O
process	O
for	O
learning	O
new	O
or	O
unfamiliar	B-I
stimuli	I-I
(	O
elaboration	O
)	O
in	O
particular	O
may	O
be	O
impaired	O
under	O
general	O
anesthesia	O
,	O
more	O
memory	O
priming	O
was	O
expected	O
for	O
familiar	O
than	O
for	O
unfamiliar	O
material	O
.	O

-DOCSTART-	O

Title	O
:	O
[	O
Clinical	O
early	O
phase	O
II	O
study	O
of	O
bicalutamide	B-I
(	I-I
Casodex	I-I
)	I-I
in	O
patients	B-P
with	I-P
prostatic	I-P
cancer	I-P
]	O
.	O

METHODS	O
:	O
The	O
patients	O
were	O
given	O
50	B-I
,	O
80	B-I
or	O
100	B-I
mg	I-I
of	I-I
bicalutamide	I-I
orally	O
once	O
a	O
day	O
in	O
fixed	O
doses	O
for	O
12	O
weeks	O
;	O
122	B-P
patients	I-P
were	O
eligible	O
for	O
evaluation	O
.	O

-DOCSTART-	O

Title	O
:	O
Comparison	O
of	O
diclofenac	B-I
sodium	I-I
and	O
morphine	B-I
sulphate	I-I
for	O
postoperative	O
analgesia	O
after	O
day	O
case	O
inguinal	O
hernia	O
surgery	O
.	O

METHODS	O
:	O
This	O
study	O
compared	O
two	O
postoperative	O
oral	O
analgesic	O
protocols	O
after	O
day	O
case	O
inguinal	O
hernia	O
repair	O
;	O
30	B-I
mg	I-I
morphine	I-I
sulphate	I-I
(	I-I
MST	I-I
)	I-I
and	O
10	B-I
mg	I-I
metoclopramide	I-I
every	O
8	O
h	O
for	O
48	O
h	O
or	O
75	B-I
mg	I-I
diclofenac	I-I
twice	O
daily	O
for	O
48	O
h	O
.	O

The	B-O
pain	I-O
reported	O
in	O
the	B-I
MST	I-I
group	O
was	O
significantly	O
greater	O
on	O
both	O
the	O
day	O
of	O
operation	O
and	O
the	O
first	O
postoperative	O
day	O
(	O
P	O
<	O
0	O
.	O
05	O
,	O
Mann	O
-	O
Whitney	O
U	O
test	O
)	O
.	O

-DOCSTART-	O

Title	O
:	O
Comparison	O
of	O
analgesic	O
effect	O
of	O
locally	B-I
and	O
systemically	B-I
administered	I-I
ketorolac	I-I
in	O
mastectomy	B-P
patients	I-P
.	O

METHODS	O
:	O
We	O
conducted	O
a	O
randomized	O
,	O
placebo	O
-	O
controlled	O
study	O
of	O
60	B-P
group	I-P
I	I-P
-	I-P
II	I-P
(	I-P
American	I-P
Society	I-P
of	I-P
Anesthesiology	I-P
criteria	I-P
)	I-P
mastectomy	I-P
patients	I-P
,	O
20	O
in	O
each	O
group	O
.	O

Near	O
the	O
end	O
of	O
surgery	O
and	O
every	O
6	O
h	O
postoperatively	O
,	O
20	B-I
ml	I-I
of	I-I
the	I-I
study	I-I
solution	I-I
containing	O
normal	B-I
saline	I-I
with	I-I
or	O
without	B-C
30	I-C
mg	I-C
of	I-C
ketorolac	I-C
were	O
administered	O
simultaneously	O
either	O
via	O
a	O
Jackson	O
-	O
Pratt	O
drain	O
or	O
intravenously	O
in	O
a	O
double	O
-	O
blind	O
fashion	O
.	O

The	B-O
quality	I-O
of	I-O
pain	I-O
control	I-O
,	O
the	B-O
amount	I-O
and	O
character	B-O
of	I-O
the	I-O
drain	I-O
fluid	I-O
,	O
incidence	B-O
of	I-O
nausea	I-O
and	O
vomiting	B-O
,	O
length	B-O
of	I-O
stay	I-O
in	I-O
the	I-O
postoperative	I-O
care	I-O
unit	I-O
,	O
and	O
amount	B-O
of	I-O
morphine	I-O
used	I-O
for	I-O
treatment	I-O
of	I-O
break	I-O
-	I-O
through	I-O
pain	I-O
were	O
recorded	O
.	O

-DOCSTART-	O

Title	O
:	O
The	O
effects	O
of	O
chronic	B-I
naltrexone	I-I
treatment	I-I
in	O
young	B-P
autistic	I-P
children	I-P
:	O
a	O
double	O
-	O
blind	O
placebo	O
-	O
controlled	O
crossover	O
study	O
.	O

METHODS	O
:	O
Drug	B-O
effects	I-O
were	O
monitored	O
with	O
behavior	B-O
checklists	I-O
rated	O
by	O
parents	O
and	O
teachers	O
,	O
and	O
ethological	B-O
playroom	I-O
observations	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Effect	O
of	O
practice	B-I
on	O
laterality	O
in	O
a	O
mental	O
rotation	O
task	O
.	O

METHODS	O
:	O
Forty	B-P
-	I-P
six	I-P
females	I-P
and	I-P
46	I-P
males	I-P
completed	O
four	B-I
blocks	I-I
of	I-I
64	I-I
trials	I-I
in	O
a	O
lateralized	O
mental	O
rotation	O
task	O
.	O

-DOCSTART-	O

Title	O
:	O
Levels	O
of	O
recombinant	B-I
human	I-I
granulocyte	I-I
colony	I-I
-	I-I
stimulating	I-I
factor	I-I
in	O
serum	O
are	O
inversely	O
correlated	O
with	O
circulating	O
neutrophil	O
counts	O
.	O

METHODS	O
:	O
We	O
investigated	O
the	O
relationship	O
between	O
serum	B-O
G	I-O
-	I-O
CSF	I-O
levels	I-O
and	O
circulating	B-O
neutrophil	I-O
counts	I-O
and	O
the	B-O
pharmacokinetics	I-O
of	O
rhG	B-I
-	I-I
CSF	I-I
for	O
patients	B-P
with	I-P
lung	I-P
cancer	I-P
who	I-P
had	I-P
been	I-P
treated	I-P
with	I-P
myelosuppressive	I-P
chemotherapy	I-P
and	I-P
then	I-P
with	I-P
subcutaneous	I-P
rhG	I-P
-	I-P
CSF	I-P
(	I-P
lenograstim	I-P
,	I-P
2	I-P
micrograms	I-P
per	I-P
kg	I-P
of	I-P
body	I-P
weight	I-P
per	I-P
day	I-P
)	I-P
.	O

Twelve	B-P
patients	I-P
were	O
randomly	O
assigned	O
to	O
four	O
groups	O
with	O
different	B-I
rhG	I-I
-	I-I
CSF	I-I
therapy	I-I
schedules	O
.	O

Serum	B-O
G	I-O
-	I-O
CSF	I-O
levels	I-O
were	O
measured	O
by	O
an	B-O
enzyme	I-O
immunoassay	I-O
method	I-O
.	O

-DOCSTART-	O

Title	O
:	O
The	O
evolving	O
clinical	O
status	O
of	O
patients	B-P
after	I-P
a	I-P
myocardial	I-P
infarction	I-P
:	O
the	O
importance	O
of	O
post	O
-	O
hospital	O
data	O
for	O
mortality	O
prediction	O
.	O

METHODS	O
:	O
An	B-P
inception	I-P
cohort	I-P
of	I-P
patients	I-P
enrolled	I-P
in	I-P
the	I-P
Beta	I-P
-	I-P
Blocker	I-P
in	I-P
Heart	I-P
Attack	I-P
Trial	I-P
(	I-P
n	I-P
=	I-P
2830	I-P
)	I-P
was	O
included	O
.	O

Forty	O
-	O
three	O
variables	O
(	O
including	O
in	O
-	O
hospital	O
and	O
post	O
-	O
hospital	O
data	O
)	O
were	O
evaluated	O
using	O
stepwise	O
logistic	O
regression	O
.	O

-DOCSTART-	O

Title	O
:	O
Age	B-I
and	O
autonomic	B-I
effects	I-I
on	O
interrelationships	O
between	O
lung	O
volume	O
and	O
heart	O
rate	O
.	O

METHODS	O
:	O
Estimates	O
of	O
respiratory	B-O
and	O
heart	B-O
rate	I-O
power	I-O
spectra	I-O
and	O
linear	B-O
transfer	I-O
functions	I-O
between	O
the	O
two	O
groups	O
were	O
generated	O
by	O
Fourier	O
analysis	O
.	O

Age	B-O
,	O
double	B-O
blockade	I-O
effects	I-O
,	O
the	B-O
age	I-O
-	I-O
drug	I-O
interactions	I-O
were	O
determined	O
by	O
analysis	O
of	O
variance	O
for	O
repeated	O
measures	O
.	O

-DOCSTART-	O

Title	O
:	O
Effects	O
of	O
age	O
at	O
introduction	O
of	O
complementary	B-I
foods	I-I
to	O
breast	B-P
-	I-P
fed	I-P
infants	I-P
on	I-P
duration	I-P
of	I-P
lactational	I-P
amenorrhea	I-P
in	I-P
Honduran	I-P
women	I-P
.	O

METHODS	O
:	O
Data	O
on	O
LA	O
were	O
collected	O
during	O
and	O
after	O
a	O
2	O
-	O
mo	O
intervention	O
trial	O
in	O
which	O
low	B-P
-	I-P
income	I-P
Honduran	I-P
women	I-P
who	I-P
had	I-P
breast	I-P
-	I-P
fed	I-P
fully	I-P
for	I-P
4	I-P
mo	I-P
were	O
randomly	O
assigned	O
to	O
one	O
of	O
three	O
groups	O
:	O
continued	B-I
full	I-I
breast	I-I
-	I-I
feeding	I-I
until	O
6	O
mo	O
(	O
FBF	B-I
,	O
n	O
=	O
50	O
)	O
,	O
introduction	B-I
of	I-I
complementary	I-I
foods	I-I
at	O
4	O
mo	O
with	O
ad	O
libitum	O
breast	O
-	O
feeding	O
from	O
4	O
to	O
6	O
mo	O
(	O
SF	B-I
,	O
n	O
=	O
47	O
)	O
,	O
or	O
introduction	B-I
of	I-I
complementary	I-I
foods	I-I
at	O
4	O
mo	O
with	O
maintenance	O
of	O
baseline	O
breast	O
-	O
feeding	O
frequency	O
from	O
4	O
to	O
6	O
mo	O
(	O
SF	B-I
-	I-I
M	I-I
,	O
n	O
=	O
44	O
)	O
.	O

Women	O
were	O
followed	O
up	O
until	O
the	O
infant	O
was	O
12	O
mo	O
of	O
age	O
,	O
or	O
later	O
if	O
menses	O
had	O
not	O
occurred	O
by	O
then	O
.	O

-DOCSTART-	O

Title	O
:	O
Intravenous	B-I
pretreatment	I-I
of	I-I
hypertonic	I-I
saline	I-I
can	O
prevent	O
systemic	O
hypotension	O
induced	O
by	O
spinal	O
anesthesia	O
.	O

METHODS	O
:	O
Sixty	B-P
ASA	I-P
class	I-P
I	I-P
patients	I-P
scheduled	I-P
for	I-P
herniorrhapy	I-P
under	I-P
spinal	I-P
anesthesia	I-P
were	O
assigned	O
randomly	O
into	O
two	O
groups	O
.	O

Group	O
1	O
=	O
patients	O
were	O
prehydrated	O
with	O
isotonic	B-I
lactated	I-I
Ringer	I-I
'	I-I
s	I-I
solution	I-I
at	O
7	O
mg	O
/	O
kg	O
(	O
n	O
=	O
30	O
)	O
;	O
Group	O
2	O
=	O
patients	O
were	O
given	O
prehydration	O
with	O
3	B-I
%	I-I
hypertonic	I-I
saline	I-I
at	O
7	O
ml	O
/	O
kg	O
(	O
n	O
=	O
30	O
)	O
.	O

Following	O
prehydration	O
,	O
arterial	B-O
blood	I-O
pressure	I-O
and	O
heart	B-O
rate	I-O
were	O
recorded	O
and	O
serum	B-O
electrolyte	I-O
concentrations	I-O
were	O
measured	O
.	O

-DOCSTART-	O

Title	O
:	O
Acute	O
rejection	O
and	O
heart	O
infection	O
rates	O
in	O
FK	B-I
506	I-I
-	I-I
versus	O
cyclosporine	B-I
A	I-I
-	O
treated	O
heart	B-P
transplant	I-P
recipients	I-P
:	O
an	O
endomyocardial	O
biopsy	O
pathologic	O
study	O
.	O

-DOCSTART-	O

Title	O
:	O
An	O
open	O
,	O
parallel	O
group	O
comparison	O
of	O
quinapril	B-I
and	O
captopril	B-I
,	O
when	O
added	O
to	O
diuretic	B-I
therapy	I-I
,	O
in	O
the	O
treatment	O
of	O
elderly	B-P
patients	I-P
with	I-P
heart	I-P
failure	I-P
.	O

METHODS	O
:	O
The	O
study	O
was	O
performed	O
at	O
a	O
single	O
centre	O
as	O
an	O
open	O
randomised	O
parallel	O
-	O
group	O
study	O
,	O
patients	O
being	O
selected	O
for	O
inclusion	O
from	O
the	O
outpatient	O
population	O
.	O

Following	O
a	O
starting	O
dose	O
of	O
either	O
2	B-I
.	I-I
5	I-I
mg	I-I
once	I-I
-	I-I
daily	I-I
quinapril	I-I
,	O
or	O
6	B-I
.	I-I
25	I-I
mg	I-I
twice	I-I
-	I-I
daily	I-I
captopril	I-I
,	O
patients	O
were	O
reviewed	O
at	O
two	O
-	O
weekly	O
intervals	O
,	O
and	O
following	O
clinical	O
assessment	O
a	O
decision	O
was	O
made	O
either	O
to	O
titrate	O
up	O
to	O
the	O
next	O
medication	O
stage	O
or	O
to	O
enter	O
the	O
patient	O
into	O
the	O
16	O
-	O
week	O
maintenance	O
phase	O
.	O

Efficacy	B-O
was	O
assessed	O
using	O
a	B-O
six	I-O
-	I-O
minute	I-O
walking	I-O
test	I-O
,	O
the	B-O
New	I-O
York	I-O
Heart	I-O
Association	I-O
(	I-O
NYHA	I-O
)	I-O
class	I-O
,	O
a	B-O
functional	I-O
lifescale	I-O
(	I-O
FLS	I-O
)	I-O
questionnaire	I-O
and	O
the	B-O
cardiothoracic	I-O
ratio	I-O
(	I-O
CTR	I-O
)	I-O
-	O
at	O
study	O
entry	O
and	O
at	O
the	O
end	O
of	O
the	O
maintenance	O
phase	O
.	O

Blood	B-O
pressure	I-O
was	O
measured	O
for	O
5	O
h	O
post	O
-	O
first	O
-	O
dose	O
of	O
medication	O
.	O

-DOCSTART-	O

Title	O
:	O
A	O
drug	O
interaction	O
study	O
between	O
ticlopidine	B-I
and	O
cyclosporin	B-I
in	O
heart	B-P
transplant	I-P
recipients	I-P
.	O

METHODS	O
:	O
Twenty	B-P
heart	I-P
-	I-P
transplant	I-P
recipients	I-P
were	O
randomised	O
into	O
either	O
a	B-I
treated	I-I
or	O
a	B-C
placebo	I-C
group	O
.	O

Blood	B-O
samples	I-O
were	O
drawn	O
for	O
time	O
-	O
course	O
evaluation	O
of	O
cyclosporin	B-O
blood	I-O
levels	I-O
over	O
a	O
period	O
of	O
12	O
h	O
,	O
following	O
the	B-I
morning	I-I
intake	I-I
of	I-I
cyclosporin	I-I
and	O
,	O
for	O
platelet	O
aggregation	O
studies	O
,	O
before	O
and	O
after	O
14	B-I
days	I-I
of	I-I
ticlopidine	I-I
administration	O
.	O

Twenty	B-O
four	I-O
-	I-O
hour	I-O
urine	I-O
samples	I-O
were	O
collected	O
for	O
6	B-O
-	I-O
beta	I-O
-	I-O
hydroxycortisol	I-O
measurements	I-O
,	O
before	O
and	O
after	O
14	O
days	O
of	O
ticlopidine	B-I
.	O

-DOCSTART-	O

Title	O
:	O
The	O
influence	O
of	O
preoperative	B-I
antibiotics	I-I
on	O
success	O
of	O
endosseous	O
implants	O
up	O
to	O
and	O
including	O
stage	O
II	O
surgery	O
:	O
a	O
study	O
of	O
2	B-P
,	I-P
641	I-P
implants	I-P
.	O

METHODS	O
:	O
As	O
part	O
of	O
the	O
comprehensive	O
Dental	O
Implant	O
Clinical	O
Research	O
Group	O
clinical	O
implant	O
study	O
,	O
the	B-O
preoperative	I-O
or	O
postoperative	B-O
use	I-O
of	I-O
antibiotics	I-O
,	O
the	B-O
type	I-O
used	I-O
,	O
and	O
the	B-O
duration	I-O
of	I-O
coverage	I-O
was	I-O
left	I-O
to	I-O
the	I-O
discretion	I-O
of	I-O
the	I-O
surgeon	I-O
.	O

These	O
data	O
were	O
recorded	O
and	O
correlated	O
with	O
failure	B-O
of	I-O
osseointegration	I-O
during	O
healing	O
(	O
stage	O
I	O
)	O
and	O
at	O
stage	O
II	O
surgery	O
(	O
uncovering	O
)	O
.	O

-DOCSTART-	O

Title	O
:	O
The	O
reliability	O
of	O
catheter	B-I
-	I-I
tip	I-I
transducers	I-I
for	O
the	O
measurement	O
of	O
intrauterine	O
pressure	O
in	O
the	O
third	O
stage	O
of	O
labour	O
.	O

METHODS	O
:	O
In	O
each	O
case	O
in	O
the	O
first	O
group	O
two	O
catheters	O
were	O
tied	O
together	O
and	O
introduced	O
transcervically	O
into	O
the	O
uterine	O
cavity	O
after	O
delivery	O
of	O
the	O
placenta	O
.	O

In	O
each	O
case	O
in	O
the	O
second	O
group	O
two	O
catheters	O
were	O
inserted	O
independently	O
into	O
the	O
same	O
uterine	O
cavity	O
.	O

The	B-O
active	I-O
and	O
cumulative	B-O
active	I-O
pressures	I-O
recorded	O
from	O
the	O
pairs	O
of	O
catheters	O
within	O
each	O
uterine	O
cavity	O
were	O
compared	O
.	O

-DOCSTART-	O

Title	O
:	O
Zolmitriptan	B-I
(	I-I
311C90	I-I
)	I-I
does	O
not	O
interact	O
with	O
fluoxetine	B-I
in	O
healthy	B-P
volunteers	I-P
.	O

METHODS	O
:	O
Twenty	B-P
volunteers	I-P
were	O
given	O
single	B-I
doses	I-I
of	I-I
fluoxetine	I-I
20	O
mg	O
or	O
an	B-C
identical	I-C
placebo	I-C
daily	O
for	O
28	O
days	O
prior	O
to	O
receiving	O
a	B-I
single	I-I
10	I-I
mg	I-I
oral	I-I
dose	I-I
of	I-I
zolmitriptan	I-I
.	O

-DOCSTART-	O

Title	O
:	O
Improved	O
survival	O
with	O
early	B-I
intensification	I-I
:	O
combined	O
results	O
from	O
the	O
Medical	O
Research	O
Council	O
childhood	O
ALL	O
randomised	O
trials	O
,	O
UKALL	O
X	O
and	O
UKALL	O
XI	O
.	O

Medical	O
Research	O
Council	O
Working	O
Party	O
on	O
Childhood	O
Leukaemia	O
.	O

METHODS	O
:	O
This	O
paper	O
examines	O
the	O
effect	O
of	O
the	B-I
addition	I-I
of	I-I
the	I-I
early	I-I
intensification	I-I
block	I-I
to	O
treatment	O
which	O
included	O
late	O
intensification	O
,	O
combining	O
the	O
data	O
from	O
UKALL	O
X	O
and	O
the	O
first	O
part	O
of	O
UKALL	O
XI	O
.	O

-DOCSTART-	O

Title	O
:	O
The	O
Treatment	O
of	O
Lead	B-P
-	I-P
exposed	I-P
Children	I-P
(	O
TLC	O
)	O
trial	O
:	O
design	O
and	O
recruitment	O
for	O
a	O
study	O
of	O
the	O
effect	O
of	O
oral	O
chelation	O
on	O
growth	O
and	O
development	O
in	O
toddlers	O
.	O

METHODS	O
:	O
TLC	O
clinical	O
sites	O
were	O
in	O
Baltimore	O
,	O
Cincinnati	O
and	O
Columbus	O
,	O
Newark	O
and	O
Philadelphia	O
.	O

Children	O
were	O
eligible	O
for	O
TLC	O
if	O
they	O
were	O
between	O
12	O
and	O
33	O
months	O
of	O
age	O
,	O
had	O
a	O
confirmed	O
blood	O
lead	O
concentration	O
between	O
20	O
and	O
44	O
micrograms	O
/	O
dL	O
and	O
lived	O
in	O
a	O
residence	O
suitable	O
for	O
lead	O
dust	O
reduction	O
.	O

Randomised	O
children	O
received	O
up	O
to	O
three	B-I
26	I-I
-	I-I
day	I-I
courses	I-I
of	I-I
succimer	I-I
or	O
placebo	B-C
,	O
and	O
were	O
then	O
followed	O
for	O
3	O
years	O
.	O

The	O
study	O
can	O
detect	O
a	B-O
three	I-O
-	I-O
point	I-O
difference	I-O
in	I-O
full	I-O
-	I-O
scale	I-O
IQ	I-O
at	O
3	O
-	O
year	O
follow	O
-	O
up	O
.	O

Statistical	O
power	O
for	O
the	O
other	O
end	O
points	O
is	O
more	O
difficult	O
to	O
estimate	O
.	O

-DOCSTART-	O

Title	O
:	O
The	O
influence	O
of	O
sequential	O
annual	B-I
vaccination	I-I
and	O
of	O
DHEA	B-I
administration	I-I
on	O
the	O
efficacy	O
of	O
the	O
immune	O
response	O
to	O
influenza	O
vaccine	O
in	O
the	B-P
elderly	I-P
.	O

METHODS	O
:	O
Seventy	B-P
-	I-P
one	I-P
elderly	I-P
volunteers	I-P
,	I-P
aged	I-P
61	I-P
-	I-P
89	I-P
years	I-P
,	O
enrolled	O
in	O
a	O
prospective	O
randomized	O
,	O
double	O
-	O
blind	O
study	O
to	O
receive	O
either	O
DHEA	B-I
(	O
50	O
mg	O
qd	O
p	O
.	O
o	O
.	O
for	O
4	O
consecutive	O
days	O
starting	O
2	O
days	O
before	O
immunization	O
)	O
or	O
placebo	B-C
.	O

Antibody	B-O
response	I-O
against	O
the	O
three	O
strains	O
of	O
vaccine	O
was	O
measured	O
before	O
and	O
28	O
days	O
after	O
vaccination	O
,	O
and	O
compared	O
between	O
previously	O
vaccinated	O
and	O
non	O
-	O
vaccinated	O
subjects	O
.	O

-DOCSTART-	O

Title	O
:	O
Treatment	O
of	O
children	B-P
with	I-P
autism	I-P
:	O
a	O
randomized	O
controlled	O
trial	O
to	O
evaluate	O
a	B-I
caregiver	I-I
-	I-I
based	I-I
intervention	I-I
program	I-I
in	O
community	O
day	O
-	O
care	O
centers	O
.	O

METHODS	O
:	O
Thirty	B-P
-	I-P
five	I-P
preschool	I-P
children	I-P
with	I-P
a	I-P
DSM	I-P
III	I-P
-	I-P
R	I-P
diagnosis	I-P
of	I-P
autism	I-P
or	I-P
pervasive	I-P
developmental	I-P
disorder	I-P
were	O
randomized	O
to	O
an	O
experimental	O
or	O
control	O
group	O
.	O

Children	O
in	O
the	O
experimental	O
group	O
were	O
enrolled	O
in	O
day	O
care	O
and	O
their	O
parents	O
and	O
child	O
care	O
workers	O
received	O
a	B-I
12	I-I
-	I-I
week	I-I
intervention	I-I
consisting	O
of	O
lectures	B-I
and	O
on	B-I
-	I-I
site	I-I
consultations	I-I
to	I-I
day	I-I
-	I-I
care	I-I
centers	I-I
.	O

In	O
addition	O
,	O
supportive	O
work	O
was	O
undertaken	O
with	O
families	O
.	O

Control	O
subjects	O
received	O
day	B-C
care	I-C
alone	I-C
.	O

-DOCSTART-	O

Title	O
:	O
Accuracy	O
and	O
feasibility	O
of	O
contrast	B-I
echocardiography	I-I
for	O
detection	O
of	O
perfusion	O
defects	O
in	O
routine	O
practice	O
:	O
comparison	O
with	O
wall	B-I
motion	I-I
and	O
technetium	B-I
-	I-I
99m	I-I
sestamibi	I-I
single	I-I
-	I-I
photon	I-I
emission	I-I
computed	I-I
tomography	I-I
.	O

The	O
Nycomed	O
NC100100	O
Investigators	O
.	O

METHODS	O
:	O
Fundamental	B-C
or	O
harmonic	B-I
MCE	I-I
was	O
performed	O
with	O
continuous	O
or	O
triggered	O
imaging	O
in	O
203	B-P
patients	I-P
with	I-P
a	I-P
previous	I-P
MI	I-P
using	I-P
bolus	I-P
doses	I-P
of	I-P
a	I-P
perfluorocarbon	I-P
-	I-P
filled	I-P
contrast	I-P
agent	I-P
(	I-P
NC100100	I-P
)	I-P
.	O

All	O
patients	O
underwent	O
single	B-I
-	I-I
photon	I-I
emission	I-I
computed	I-I
tomography	I-I
(	I-I
SPECT	I-I
)	I-I
after	O
the	B-I
injection	I-I
of	I-I
technetium	I-I
-	I-I
99m	I-I
(	I-I
Tc	I-I
-	I-I
99m	I-I
)	I-I
sestamibi	I-I
at	O
rest	O
.	O

Quantitative	B-O
and	O
semiquantitative	B-O
SPECT	I-O
,	O
wall	B-O
motion	I-O
and	O
digitized	B-O
echocardiographic	I-O
data	I-O
were	O
interpreted	O
independently	O
.	O

The	B-O
accuracy	I-O
of	I-O
MCE	I-O
was	O
assessed	O
for	O
detection	B-O
of	I-O
segments	I-O
and	O
patients	B-O
with	I-O
moderate	I-O
and	I-O
severe	I-O
sestamibi	I-O
-	I-O
SPECT	I-O
defects	I-O
,	O
as	O
well	O
as	O
for	O
detection	B-O
of	I-O
patients	I-O
with	I-O
extensive	I-O
perfusion	I-O
defects	I-O
(	I-O
>	I-O
12	I-O
%	I-O
of	I-O
left	I-O
ventricle	I-O
)	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Ten	O
-	O
year	O
results	O
of	O
a	O
randomised	O
trial	O
comparing	O
cisplatin	B-I
with	O
cisplatin	B-I
and	O
cyclophosphamide	B-I
in	O
advanced	O
,	O
suboptimally	O
debulked	O
ovarian	O
cancer	O
.	O

METHODS	O
:	O
176	B-P
eligible	I-P
patients	I-P
with	I-P
advanced	I-P
suboptimally	I-P
operated	I-P
ovarian	I-P
carcinoma	I-P
were	O
randomly	O
allocated	O
to	O
receive	O
either	O
cisplatin	B-I
75	O
mg	O
/	O
m2	O
or	O
cisplatin	B-I
50	O
mg	O
/	O
m2	O
and	O
cyclophosphamide	B-I
500	O
mg	O
/	O
m2	O
(	O
CP	O
)	O
every	O
28	O
days	O
for	O
six	O
courses	O
.	O

METHODS	O
:	O
Thirty	B-P
-	I-P
seven	I-P
platinum	I-P
-	I-P
resistant	I-P
and	I-P
27	I-P
platinum	I-P
-	I-P
sensitive	I-P
tumours	I-P
were	O
treated	O
with	O
carboplatin	B-I
or	O
cisplatin	B-I
as	O
second	O
-	O
line	O
therapy	O
.	O

-DOCSTART-	O

Title	O
:	O
Comparative	O
efficacy	O
and	O
safety	O
of	O
calcium	B-I
carbasalate	I-I
plus	O
metoclopramide	B-I
versus	O
ergotamine	B-I
tartrate	I-I
plus	O
caffeine	B-I
in	O
the	O
treatment	O
of	O
acute	O
migraine	O
attacks	O
.	O

METHODS	O
:	O
A	B-P
total	I-P
of	I-P
296	I-P
patients	I-P
fulfilling	I-P
the	I-P
International	I-P
Headache	I-P
Society	I-P
diagnostic	I-P
criteria	I-P
for	I-P
migraine	I-P
were	O
enrolled	O
.	O

In	O
total	O
,	O
one	O
or	O
two	O
migraine	O
attacks	O
were	O
treated	O
in	O
268	O
and	O
235	O
patients	O
,	O
respectively	O
.	O

The	O
primary	O
endpoint	O
for	O
the	O
first	O
treated	O
attack	O
was	O
headache	B-O
relief	I-O
,	O
with	O
intensity	O
decreasing	O
from	O
moderate	O
or	O
severe	O
to	O
mild	O
or	O
absent	O
2	O
h	O
after	O
drug	O
intake	O
.	O

Usual	O
secondary	O
efficacy	O
endpoints	O
were	O
assessed	O
.	O

-DOCSTART-	O

Title	O
:	O
The	O
preparation	O
of	O
patients	B-P
for	I-P
cardiac	I-P
surgery	I-P
.	O

-DOCSTART-	O

Title	O
:	O
Network	O
support	O
for	O
drinking	O
,	O
Alcoholics	O
Anonymous	O
and	O
long	O
-	O
term	O
matching	O
effects	O
.	O

METHODS	O
:	O
Outpatients	O
were	O
re	O
-	O
interviewed	O
3	O
years	O
following	O
treatment	O
.	O

ANCOVAs	O
tested	O
the	O
matching	O
hypothesis	O
.	O

Outpatients	B-P
from	I-P
five	I-P
clinical	I-P
research	I-P
units	I-P
distributed	I-P
across	I-P
the	I-P
United	I-P
States	I-P
.	O

Eight	B-P
hundred	I-P
and	I-P
six	I-P
alcohol	I-P
-	I-P
dependent	I-P
clients	I-P
.	O

Clients	O
were	O
randomly	O
assigned	O
to	O
one	O
of	O
three	B-I
12	I-I
-	I-I
week	I-I
,	I-I
manually	I-I
-	I-I
guided	I-I
,	I-I
individual	I-I
treatments	I-I
:	O
TSF	B-I
,	O
MET	B-I
or	O
Cognitive	B-I
Behavioral	I-I
Coping	I-I
Skills	I-I
Therapy	I-I
(	I-I
CBT	I-I
)	I-I
.	O

Network	B-O
support	I-O
for	I-O
drinking	I-O
prior	I-O
to	I-O
treatment	I-O
,	O
Alcoholics	B-O
Anonymous	I-O
(	I-O
AA	I-O
)	I-O
involvement	I-O
during	I-O
and	O
following	B-O
treatment	I-O
,	O
percentage	B-O
of	I-O
days	I-O
abstinent	I-O
and	O
drinks	B-O
per	I-O
drinking	I-O
day	I-O
during	O
months	O
37	O
-	O
39	O
.	O

-DOCSTART-	O

Title	O
:	O
[	O
Effect	O
of	O
alanyl	B-I
-	I-I
glutamine	I-I
in	O
postoperative	O
total	O
parenteral	O
nutrition	O
on	O
postoperative	O
immunosuppression	O
and	O
morbidity	O
.	O

Preliminary	O
results	O
of	O
a	O
prospective	O
randomized	O
study	O
]	O
.	O

METHODS	O
:	O
To	O
analyze	O
immune	B-O
competence	I-O
,	O
the	B-O
expression	I-O
of	I-O
CD3	I-O
,	O
CD4	B-O
,	O
and	O
CD8	B-O
on	I-O
lymphocytes	I-O
and	O
of	O
HLA	B-O
-	I-O
DR	I-O
and	O
CD14	B-O
on	I-O
monocytes	I-O
as	O
well	O
as	O
the	B-O
plasma	I-O
levels	I-O
of	I-O
IL	I-O
-	I-O
6	I-O
and	O
IL	B-O
-	I-O
10	I-O
was	O
evaluated	O
before	O
,	O
1	O
,	O
2	O
,	O
4	O
,	O
and	O
7	O
days	O
after	O
surgery	O
.	O

-DOCSTART-	O

Title	O
:	O
The	O
influence	O
of	O
ventricular	O
fibrillation	O
duration	O
on	O
defibrillation	O
efficacy	O
using	O
biphasic	B-I
waveforms	I-I
in	O
humans	O
.	O

METHODS	O
:	O
Thirty	B-P
patients	I-P
undergoing	I-P
primary	I-P
ICD	I-P
implantation	I-P
or	I-P
pulse	I-P
generator	I-P
replacement	I-P
were	O
randomly	O
assigned	O
to	O
have	O
the	B-O
DFT	I-O
determined	O
using	O
biphasic	B-I
shocks	I-I
at	O
two	O
durations	O
of	O
VF	O
each	O
(	O
5	O
and	O
10	O
s	O
,	O
10	O
and	O
20	O
s	O
or	O
5	O
and	O
20	O
s	O
)	O
.	O

